Targeting PPARD Reprograms Immune Cell Metabolism Against Solid Tumours
Shifting immune cell fuel utilisation from glucose reliance toward fatty acid oxidation restores T-cell vigour across multiple solid tumour models.
The nuclear receptor peroxisome proliferator-activated receptor delta (PPARD) has long carried an ambiguous reputation in oncology because tumour cells frequently co-opt it to accelerate their own proliferation. A study led by researchers at the Salk Institute demonstrated that selective activation of PPARD inside tumour-infiltrating CD8+ T cells produces the opposite effect: it equips them to clear malignant tissue.
Inside an immunosuppressive microenvironment, tumours deplete local glucose and suffocate normal immune responses. The researchers observed that administering a selective PPARD agonist altered T-cell lipid metabolism, increasing mitochondrial fatty acid oxidation rates by more than 40 percent. In murine cohorts with established colorectal, breast, and melanoma tumours, this metabolic switch doubled median survival times compared to vehicle controls.
Reprogramming Immune Fuel Preference
Popular longevity protocols frequently promote general metabolic flexibility through fasting or exogenous fuels without verifying cell-type-specific responses. This research confirms that cellular energy pathways behave differently depending on the tissue and immune context. Discuss immunometabolic screening with your physician before adopting experimental metabolic modulators that promise systemic resilience without targeted controls.
The longer view
One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.